

Avere Beauty Now Offering FDA-Approved Skinpen Micro-needling at its Pittsburgh Med Spa

An industry leader in anti-aging treatments and beauty services is now offering a unique solution that has been approved by the federal government.

PITTSBURGH, PENNSYLVANIA, UNITED STATES, August 14, 2020

/EINPresswire.com/ -- Representatives with [Avere Beauty](#) announced today that it is now offering a new, revolutionary micro-needling device, which has been approved by the U.S. Food and Drug Administration (FDA) for micro-needling.



Avere Beauty Spokesperson Alyssa Luciano RN explained the device, SkinPen, is the first FDA-approved micro-needling device that causes tiny perforations in the skin to stimulate collagen production. The result is a remodeling of scar tissue while keeping the skin intact.

The [SkinPen micro-needling](#) is being offered at the company's location at 3495 Butler St., Suite G01, Pittsburgh PA 15201.

FDA approval is important because it validates through verified research and clinical trials that the product works and is safe for the consumers and the general public. The FDA examines, tests, and approves a wide range of items for medical use, including drugs, medical devices, food, cosmetics, and many other health-related products. In the simplest terms, "FDA approval" means that the FDA has decided that users will directly benefit from the approved item, which in this case, is SkinPen.

SkinPen, according to Luciano, works to diminish the appearance of large pores. The SkinPen creates micro-injuries in the skin, triggering the body's immune response. This response naturally produces collagen and elastin. The collagen and elastin help to tighten the skin and reduce the appearance of large pores.

The FDA-approved device is also effective against facial scarring, especially acne scarring, which

can be a problematic issue for many people.

Luciano revealed that the SkinPen helps scarring by causing micro-injuries to the skin to trigger the body's immune system to remodel the scar tissue. The scar remodeling occurs while still ensuring the skin's overall structure is still intact. As for results, during a six-month clinical trial, the use of the SkinPen helped to improve acne scars in 90 percent of patients.

As for specific details on how it works, the SkinPen utilizes micro-needling in three phases. In Phase 1 – the Inflammation phase, the device works by piercing the skin, triggering the individual's immune system to disinfect the wounds, increasing blood flow, and creates new tissue.

In Phase II - the Proliferation phase, the wound is rebuilt with new granulation cells, which are part of the extracellular matrix. A new network of blood cells is created. And in Phase III - the Remodeling phase, the wound is replaced with new dermal tissues and blood vessels.

For more information, please visit www.averebeauty.com/blog and <https://www.averebeauty.com/about-us>.

###

About Avere Beauty

We are a group of clinicians and medical professionals, local to Pittsburgh, who believe in self-care, beauty, and confidence. At Avere Beauty, we believe you have the power to look as good as you feel. With our anti-aging treatments and beauty services, we offer you a chance to revitalize and refresh your looks.

Contact Details:

Frank Udavcak
Business Director

3495 Butler Street
Suite G01
Pittsburgh, PA 15201
United States

Phone: (949) 424-8240

Source: Avere Beauty

Frank Udavcak

Avere Beauty

+1 949-424-8240

[email us here](#)

Visit us on social media:

[Facebook](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/524009915>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.